<Back to Therapeutic Areas

Immunology

GSK Immunology will have a presence at the meetings listed below. Please visit us at our medical affairs booths to view our medical information.

Meet Us

RWCS | Feb 10-13, 2021 | Maui, HI | Virtual

ACR-SOTA | Mar 26-28, 2021 | New Orleans, LA

NKF | Apr 6-10, 2021 | Virtual

AWIR | Aug 12-15, 2021 | Hilton Head, SC

CCR East | Aug 12-15, 2021 | Destin, FL

CCR West | Sep 18-21, 2021 | Coronado, CA

ASN | Nov 2-7, 2021 | San Diego, CA

ACR | Nov 5-9, 2021 | San Francisco, CA

View information about our marketed products Benlysta and Nucala including prescribing information, material safety data sheets and environmental risks assessments pertaining to these products.

View educational videos from GSK Immunology on selected disease states related to our products.

HES

HES Mechanism of Disease (6:24)

SLE

On-Demand Webinars

Presented By: Dr. Michelle Petri MD, MPH

Unrecognized Impact of Organ Damage in SLE (Brief) (6:03)

Unrecognized Impact of Organ Damage in SLE (Full length) (35:11)

EGPA

On-Demand Webinars

Presented by: Dr. Michael E. Wechsler, MD, MMSc

EGPA: Pathogenesis, Diagnosis, and Management (28:06)


EGPA Mechanism of Disease (3:54)

View our ongoing, innovative research with autoimmune diseases.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Phase II Phase III Phase IV

SABLE: Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry

NCT01729455

Belimumab Pregnancy Registry

NCT01532310

BLISS-LN: Belimumab in Active Lupus Nephritis

NCT01639339

BLISS-BELIEVE: Belimumab Subcutaneous in Combination with Rituximab in Adult SLE

NCT03312907
RHEUMATOID ARTHRITIS (RA) Phase II Phase III Phase IV

ContRAst-1: Otilimab vs Placebo and Tofacitinib in Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to Methotrexate

NCT03980483

ContRAst-2: Otilimab vs Placebo and Tofacitinib in Moderately to Severely Active RA who have Inadequate Response to Conventional Synthetic DMARDs

NCT03970837

ContRAst-3: Otilimab vs Placebo and Sarilumab in Moderately to Severely Active RA with Inadequate Response to Biologic DMARDs and/or JAKI

NCT04134728

Mechanistic Study of Otilimab Plus Methotrexate in Active Rheumatoid Arthritis Despite Treatment With DMARDs

NCT02799472
(Phase IIa)

Otilimab Plus Methotrexate in Active Moderate-Severe Rheumatoid Arthritis

NCT02504671
(Phase IIb)
INFLAMMATORY BOWEL DISEASE Phase II Phase III Phase IV

Study of anti-LAG3 in Ulcerative Colitis

NCT03893565
EOSINOPHILIC GRANULOMATOSIS
WITH POLYANGIITIS (EGPA)
Phase II Phase III Phase IV

VCRC-VPPRN EGPA Registry (Observational Study)*

NCT00315380 (Observational)
SJÖGREN’S SYNDROME Phase II Phase III Phase IV

Belimumab Subcutaneous and Intravenous Rituximab Co-Administered in Primary Sjögren’s Syndrome

NCT02631538
SYSTEMIC SCLEROSIS Phase II Phase III Phase IV

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

NCT03041025
Definitions:
  • BLyS = B Lymphocyte Stimulator;
  • DMARDs = Disease-Modifying Anti-Rheumatic Drugs;
  • GM-CSF = Granulocyte-Macrophage Colony-Stimulating Factor;
  • JAKI = Janus Kinase Inhibitor;
  • LAG-3 = Lymphocyte Activation Gene-3 Protein;
  • OSM = Oncostatin M;
  • VCRC = Vasculitis Clinical Research Consortium;
  • VPPRN = Vasculitis Patient-Powered Research Network
  • *Supported in part by GSK

Unlocking the secrets of the immune system (0:29)

Access important product resources such as the Belimumab Vial Calculator and Blood Eosinophil Unit Conversion Calculator and search for scientific literature.

  Contact Us